Published by Pinnacle Pulse, maker of a self-tracking app. We have no affiliate or sales relationship with any peptide seller. Editorial policy →

BPC-157: what the research shows, and what it doesn’t

By Pinnacle Pulse Editorial Team · Status as of 16 October 2026 · Next scheduled update: 14 January 2027

Short answer: BPC-157 has mostly been studied in rats, mice and cell cultures. A 2025 systematic review found 36 eligible studies, and 35 of them were preclinical. The human record is a chart review and a two-person pilot, neither with a control group. No randomized controlled trial is indexed in PubMed, and safety in people has not been established.

What BPC-157 is

BPC-157 is a synthetic peptide made of 15 amino acids. The letters stand for “body protection compound”, a nod to its reported origin as a fragment of a protein in gastric juice. It is not authorized as a medicine in the European Union, and FDA has never approved a drug containing it. What circulates online is sold outside the pharmaceutical supply chain, usually labeled as a research chemical.

That last point is easy to skip past. Nobody checks those vials the way a regulator checks a licensed drug, so even a perfect study would tell you little about what is in them.

What has been studied

Cells and animals

This is where nearly all of the literature sits. In 2025 a group of orthopaedic researchers went through 544 records for a systematic review in the HSS Journal and kept 36 studies. Thirty-five were preclinical. The animal work is mostly injury models in rodents (tendon, ligament, muscle, bone), and the authors of those papers report faster or better healing in treated animals. Whether a rat’s tendon is a decent stand-in for a human one is a fair question, and the history of drug development suggests caution.

The same review flagged something less discussed. It found no clinical safety data worth the name and pointed to risks that come with unregulated manufacturing, including contamination.

One animal paper is worth knowing about because it tempers the simplest story. Researchers in Xi’an measured how BPC-157 behaves in rats and beagle dogs in 2022. The intact peptide had a half-life of under 30 minutes, and it was broken down into small fragments and then single amino acids. That does not rule out an effect. It does mean “what the body actually sees” is a harder question than the marketing implies.

People

The human evidence fits on an index card.

A 2021 retrospective chart review from a private clinic in Orlando looked at 17 people who had received knee injections of BPC-157, some of them combined with thymosin beta-4. Sixteen were reached by phone months later and asked to recall how bad their pain had been before the injection and how much it had helped. Most said it had helped. There was no control group, no validated scoring tool, and the patients were remembering pain from six months to a year earlier.

A 2025 pilot from a Florida clinic gave intravenous BPC-157 to two adults over three days and reported no side effects and no changes in standard blood tests. Both participants had received the peptide intravenously before joining. Two people over three days can’t tell you much about safety, and the authors themselves call for further studies.

When we searched PubMed on 16 October 2026 for BPC-157 limited to randomized controlled trials or clinical trials, the query returned zero records.

What FDA concluded

FDA looked at the substance in 2026 because it had been nominated for use by compounding pharmacies. In its briefing document for the advisory committee meeting of 23 July 2026, FDA staff proposed that BPC-157 should not be added to the list of substances that compounders may use. The agency’s published concerns include possible immune reactions, impurities and difficulty characterizing the active ingredient, and very little information on safety in humans.

What the research does not show

It does not show that BPC-157 works in people for anything. There is no placebo-controlled trial to point to, so every human claim rests on uncontrolled reports.

It does not show that BPC-157 is safe. Absence of reported side effects in two people, or in a phone survey of sixteen, is not a safety finding. Nothing is known about long-term use.

The animal results cannot be read across to humans as they stand. Doses, routes and injury models in rodents differ from anything a person would encounter, and the fast breakdown seen in the 2022 pharmacokinetic study adds another layer of uncertainty.

And none of this research tells you what a product bought online contains. The studies used material made for the study.

BPC-157 is not an authorized medicine in the EU. In the US it is on neither of FDA’s two lists for compounding pharmacies; FDA’s compounding advisory committee was asked to vote on it in July 2026, but such votes don’t bind FDA, and no proposed rule had appeared in the Federal Register by 16 October 2026. WADA names BPC-157 under class S0, so it is prohibited at all times for athletes covered by anti-doping rules. The details, with dates and sources, are on our page Is BPC-157 legal?.

FAQ

Has BPC-157 been tested in humans?

Barely. The published human data are a retrospective chart review of 16 people reached by phone and a pilot study with two participants. Neither had a control group, and no randomized controlled trial is indexed in PubMed.

Is BPC-157 safe?

Nobody can say. A 2025 systematic review found no meaningful clinical safety data, and FDA lists limited human safety information and possible immune reactions among its concerns.

Does the FDA advisory committee vote mean BPC-157 works?

No. The committee advises FDA on whether a substance may be used in compounding, and its vote is non-binding. FDA’s own staff had proposed against adding BPC-157, and the vote does not create new evidence about effects in people.

Why do animal results get so much attention?

Because there is little else. Most of the 36 studies in the 2025 review were in animals, and rodent injury models often fail to predict what happens in humans.

Sources

  • Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. PMID 40756949
  • He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol. 2022;13:1026182. PMID 36588717
  • Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435
  • Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20-24. PMID 40131143
  • PubMed search “BPC-157 AND (randomized controlled trial[pt] OR clinical trial[pt])”, run 16 October 2026 via NCBI E-utilities: 0 records. (checked 16 October 2026)
  • FDA. FDA briefing document, Pharmacy Compounding Advisory Committee, July 2026. fda.gov/media/193342/download
  • FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
  • FDA. Certain bulk drug substances for use in compounding that may present significant safety risks. fda.gov
  • WADA. 2027 Prohibited List, class S0. wada-ama.org
  • Sikirić P, et al. Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress. Dig Dis Sci. 1997;42(3):661-71. PMID 9073154 (checked 16 October 2026)
  • FDA. Pharmacy Compounding Advisory Committee, July 23-24, 2026: questions for the committee (PDF), checked 16 October 2026. fda.gov/media/193711/download
  • Federal Register. Search of FDA documents published since 1 April 2026 for BPC-157, TB-500 and the 503A and 503B bulks lists, run 16 October 2026: no proposed or final rule. federalregister.gov

Facts last checked: 16 October 2026.

About this article

Written by: the Pinnacle Pulse Editorial Team, the people who make the Pinnacle Pulse app. We work only from primary sources such as regulators, legal texts, trial registries and PubMed, and we remove claims we can’t check against one.

This article has not been reviewed by a physician. It is general information, not medical advice.

Spotted an error? Our editorial policy explains how to report it and how we correct mistakes.

Change log

  • 16 October 2026: First published.

From the makers of this site: Pinnacle Pulse is a neutral tracking app. We don’t sell or recommend any substance. About Pinnacle Pulse

This article is for general information only. It is not medical advice and does not recommend the use of any substance. Decisions about medicines belong with a qualified healthcare professional.